Across the clinical research ecosystem, one truth continues to surface: time to activation matters more than ever. Delays in study startups don’t just slow recruitment. They shorten enrollment windows, frustrate investigators, and can ultimately determine whether a site remains competitive for future trials. Yet despite years of attention, many organizations still struggle to consistently activate studies within industry expectations.
